Aclaris Therapeutics (ACRS) announced that it has initiated a randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug in patients with moderate-to-severe atopic dermatitis. Top line results are expected in the second half of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Optimistic Buy Rating for Aclaris Therapeutics Driven by Promising Dermatology Pipeline Developments
- Wedbush bullish on Aclaris Therapeutics, initiates with an Outperform
- Aclaris Therapeutics initiated with an Outperform at Wedbush
- Aclaris Therapeutics price target lowered to $16 from $20 at H.C. Wainwright
- Aclaris Therapeutics: Promising Pipeline and Strategic Developments Drive Buy Rating